You are here:

lacosamide (Vimpat)

Advice

in the absence of a submission from the holder of the marketing authorisation

lacosamide (Vimpat) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: lacosamide (Vimpat)
SMC Drug ID: 1231/17
Manufacturer: UCB Pharma Ltd
Indication: As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 March 2017

Back